In the latest market close, CRISPR Therapeutics AG (CRSP) reached $37.77, with a -0.03% movement compared to the previous day. This change lagged the S&P 500's 0.13% gain on the day. On the other hand ...

BofA lowered the firm’s price target on Crispr Therapeutics (CRSP) to $80 from $86 and keeps a Buy rating on the shares. While Q1 earnings ...

The recent wave of layoffs and financial troubles at CRISPR-focused startups should not tarnish the promise of CRISPR.

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Gene editing and many other useful biotechnology tools came from studies of bacteria fighting off viral invaders. But ...

While much is known about pluripotency—the ability to differentiate into any other cell type in the body and to divide ...

A longstanding mystery in Parkinson's disease research has been why some individuals carrying pathogenic variants that increase their risk of PD go on to develop the disease, while others who also ...

Gene editing technologies have cemented their place as a valued method in the biological toolkit used by researchers around the globe.

Colossal Biosciences said it used ancient DNA from the extinct species to create three dire wolf pups named Romulus, Remus ...

Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Summit Therapeutics (NASDAQ: SMMT), and Viking Therapeutics (NASDAQ: VKTX) as stocks worth buying now. Prosper Junior Bakiny (CRISPR ...

RAPID-CRISPR test quickly and accurately diagnoses acute promyelocytic leukemia, a rare and aggressive blood cancer, with ...

Investigators have developed STITCHR, a new gene editing tool that can insert therapeutic genes into specific locations without causing unwanted mutations. The system can be formulated completely as ...